EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications

Adil Farooq Wali iD, Abid Reza Ansari iD, Prince Ahad Mir iD, Mohamed El-Tanani iD, Rasha Babiker iD, Md Sadique Hussain iD, Jasreen Uppal iD, Asma Ishrat Zargar, Reyaz Hassan Mir iD

Pharmaceuticals · 27.08.2025 · 18 (9) · 1281

DOI: 10.3390/ph18091281 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 27.08.2025. Verfasst von Adil Farooq Wali und 8 weiteren Autor:innen. Beteiligte Einrichtung: RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, continues to pose a significant global health burden due to its high mortality rate. In addition to genetic alterations, epigenetic aberrations, including DNA methylation, histone modifications, chromatin remodeling, and noncoding RNA (ncRNA) dysregulation, play critical roles in HCC initiation and progression. Notably, miR-375 and miR-483-5p are among the most dysregulated miRNAs in HCC, with their altered expression levels closely associated with tumor stage and patient survival. These epigenetic modifications offer promising therapeutic avenues due to their reversibility and dynamic nature. Furthermore, specific epigenetic signatures such as CDH1 promoter hypermethylation and HOTAIR overexpression are being explored as potential biomarkers for early detection and treatment response. In this chapter, we review recent advances in the epigenetic landscape of HCC and discuss their diagnostic and therapeutic implications, highlighting their potential to improve patient outcomes through personalized medicine approaches.

Schlagwörter

Stichwörter der Autor:innen

DNA methylationepigeneticshistone methylationliver damagencRNAs (noncoding ribonucleic acid)

Autor:innen und Institutionen

  • RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates.
  • Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar (Mohali) 160062, Punjab, India.
  • Department of Pharmacognsoy and Phytochemistry, Khalsa College of Pharmacy, G.T. Road, Amritsar 143002, Punjab, India.
  • Department of Physiology, RAK College of Medical Sciences, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates.
  • Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun 248007, Uttarakhand, India.
  • Pharmacology Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar 190006, Jammu and Kashmir, India.

ORCID-Profile: Adil Farooq Wali, Abid Reza Ansari, Prince Ahad Mir, Mohamed El-Tanani, Rasha Babiker, Md Sadique Hussain, Jasreen Uppal, Reyaz Hassan Mir

Zitieren

APA

Wali, A. F., Ansari, A. R., Mir, P. A., El-Tanani, M., Babiker, R., Hussain, M. S., Uppal, J., Zargar, A. I., & Mir, R. H. (2025). Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications. Pharmaceuticals, 18(9), 1281. https://doi.org/10.3390/ph18091281

Vancouver

Wali AF, Ansari AR, Mir PA, El-Tanani M, Babiker R, Hussain MS, et al. Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications. Pharmaceuticals. 2025;18(9):1281. doi:10.3390/ph18091281

BibTeX
@article{Wali2025,
  author = {Wali, Adil Farooq and Ansari, Abid Reza and Mir, Prince Ahad and El-Tanani, Mohamed and Babiker, Rasha and Hussain, Md Sadique and Uppal, Jasreen and Zargar, Asma Ishrat and Mir, Reyaz Hassan},
  title = {Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {9},
  pages = {1281},
  doi = {10.3390/ph18091281}
}
Kostenlos starten →